GlassScriptPhysician profile
David Bing Zhen
NPI 1568758431
$65,161.77
in general payments reported to CMS, 2019-2025
17 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,528 · 2020: $4,581 · 2021: $149 · 2022: $4,710 · 2023: $10K · 2024: $24K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Travel and Lodging: $15K · Honoraria: $9,170 · Food and Beverage: $1,601 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,169.50 |
| Travel and Lodging | $15,185.07 |
| Honoraria | $9,170.00 |
| Food and Beverage | $1,601.45 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16,703.28 | 2024-2025 | Opdivo |
| Exelixis INC. | $12,163.31 | 2024-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $10,126.88 | 2023 | Lenvima, Keytruda |
| Boehringer Ingelheim International Gmbh | $7,974.50 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $5,159.03 | 2020-2025 | Imfinzi |
| Ipsen Biopharmaceuticals, INC | $4,995.84 | 2019-2022 | |
| Daiichi Sankyo INC. | $4,743.64 | 2020-2024 | Enhertu |
| Legend Biotech USA INC. | $1,460.00 | 2024 | |
| Astrazeneca Uk Limited | $1,176.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $171.99 | 2024 | |
| Pfizer INC. | $135.00 | 2024 | |
| Cleerly, INC. | $130.76 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Servier Pharmaceuticals LLC | $111.51 | 2022 | |
| Genentech USA, INC. | $46.49 | 2024 | |
| Genentech, INC. | $34.58 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $28.65 | 2025 | Vyloy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zhen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.